Evidence map›Paper›PMID 23318690›Full record

ArticleCardiovascular drugs and therapy2013

Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts.

Xi-Ming Yang, Yanping Liu, Lin Cui, Xiulan Yang, Yongge Liu, Narendra Tandon, Junichi Kambayashi, James M Downey, Michael V Cohen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular drugs and therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Do We Really Need Aspirin Loading for STEMI?Cardiovascular drugs and therapy · 2022
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xi-Ming YangDepartment of Physiology, MSB 3050, University of South Alabama College of Medicine, Mobile, AL 36688, USA.
Yanping Liu
Lin Cui
Xiulan Yang
Yongge Liu
Narendra Tandon
Junichi Kambayashi
James M Downey
Michael V Cohen
University of South Alabama · USOtsuka (United States) · US

Funding

PHYSICAL FACTORS AND CORONARY FLOWR01HL020648 · NHLBI · UNIVERSITY OF SOUTH ALABAMA · PI DOWNEY, JAMES M · 1985 to 2011
$2.7M
NHLBI NIH HHS HL-20648NHLBI NIH HHS R01 HL020648
6 · The paper itself

Abstract

backgroundRecent studies in rabbits have demonstrated that platelet P2Y12 receptor antagonists are cardioprotective, and that the mechanism is surprisingly not related to blockade of platelet aggregation but rather to triggering of the same signal transduction pathway seen in pre- and postconditioning. We wanted to determine whether this same cardioprotection could be documented in a primate model and whether the protection was limited to P2Y12 receptor antagonists or was a class effect.

methodsThirty-one macaque monkeys underwent 90-min LAD occlusion/4-h reperfusion.

resultsThe platelet P2Y12 receptor blocker cangrelor started just prior to reperfusion significantly decreased infarction by an amount equivalent to that seen with ischemic postconditioning (p < 0.001). For any size of risk zone, infarct size in treated hearts was significantly smaller than that in control hearts. OM2, an investigational murine antibody against the primate collagen receptor glycoprotein (GP) VI, produced similar protection (p < 0.01) suggesting a class effect. Both cangrelor and OM2 were quite effective at blocking platelet aggregation (94 % and 97 %, respectively).

conclusionsThus in a primate model in which infarct size could be determined directly platelet anti-aggregatory agents are cardioprotective. The important implication of these investigations is that patients with acute myocardial infarction who are treated with platelet anti-aggregatory agents prior to revascularization may already be in a postconditioned state. This hypothesis may explain why in recent clinical trials postconditioning-mimetic interventions which were so protective in animal models had at best only a modest effect.

Indexed as

Adenosine MonophosphateAnimalsAntibodiesBlood PressureHeart RateMacaca fascicularisMaleMyocardial InfarctionPlatelet AggregationPlatelet Aggregation InhibitorsPlatelet Membrane GlycoproteinsPurinergic P2Y Receptor AntagonistsAdenosine MonophosphateAntibodiescangrelorPlatelet Aggregation InhibitorsPlatelet Membrane Glycoproteinsplatelet membrane glycoprotein VIPurinergic P2Y Receptor Antagonists

Identifiers

PMID23318690
PMCPMC3816632
OpenAlexW1989000968

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.